ПРИМЕНЕНИЕ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ ПРИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ И НОВЫЕ ВОЗМОЖНОСТИ
https://doi.org/10.20514/2226-6704-2013-0-2-57-64
Abstract
Contemporary Russian and international experience of prophylaxis of thromboembolic complications of atrial fibrillation indicates that the most popular strategy for the prevention of stroke with warfarin is far from optimum. Measures proposed to improve it (physicians’ knowledge of pharmacodynamics features, pharmacokinetics and pharmacogenetics of the drug, regular monitoring of International Normalized Ratio) can not always be implemented in clinical practice. Introduction of new anticoagulants, as effective as warfarin, but more convenient to use, is very important now. Such anticoagulant is rivaroxaban (Xarelto). Authors believe that comparable safety with warfarin and not inferior/superior safety, ease of dosing, no need for laboratory monitoring during therapy, no adverse interactions with medications and food products will allow rivaroxaban to increase significantly the compliance of doctors and patients to anticoagulant therapy in the near future.
About the Authors
Г. И. Сторожаков
ГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова»
Russian Federation
кафедра госпитальной терапии No 2 на базе ГКБ No 12, г. Москва
Russian Federation
кафедра госпитальной терапии No 2 на базе ГКБ No 12, г. Москва
С. Н. Борисов
ГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова»
Russian Federation
кафедра госпитальной терапии No 2 на базе ГКБ No 12, г. Москва
Russian Federation
кафедра госпитальной терапии No 2 на базе ГКБ No 12, г. Москва
Г. Е. Гендлин
ГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова»
Russian Federation
кафедра госпитальной терапии No 2 на базе ГКБ No 12, г. Москва
Russian Federation
кафедра госпитальной терапии No 2 на базе ГКБ No 12, г. Москва
А. В. Мелехов
ГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова»
Russian Federation
кафедра госпитальной терапии No 2 на базе ГКБ No 12, г. Москва
Russian Federation
кафедра госпитальной терапии No 2 на базе ГКБ No 12, г. Москва
References
1. Козлова Т.В., Таратута Т.В. Возможности оптимизации анти- коагулянтной терапии варфарином // РМЖ 2008; 16(11):1532– 1535.
2. Фонякин А.В., Суслина З.А., Гераскина Л.А. Стратификация причин кардиоэмболического инсульта // Неврологический журн. No 2. 2002. С. 8–12.
3. 2008 Annex 1 Summary of Product Characteristics Rivaroxaban. http://www.xarelto.com/html/downloads/Xarelto_Summary_of_ Product_Characteristics_30sept2008.pdf
4. Bounameaux H. The novel anticoagulants: entering a new era. Swiss Med Wkly 2009; 139(5-6):60–64.
5. Carlsson J., Miketic S., Flicker E., Erdogan A., Haun S. et al. Neurological events in patients with atrial fibrillation: outcome and preventive practices. Z Kardiol. 2000 Dec;89(12):1090–7.
6. Christensen T.D., Johnsen S.P., Hjordtal V.E. et al. Self-management of oral anticoagulant therapy: a systematic rewiew and meta- analysis. Int J Cardiol 2007; 118(1):54–61.
7. Food and Drug Administration. FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee. September 8, 2011.
8. Fox K.A., Piccini J.P., Wojdyla D., Becker R.C., Halperin J.L. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011 Oct;32(19):2387–94.
9. Furberg C.D., Psaty B.M., Manolio T.A. et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236–41.
10. Fuster V., Ryden L.E., Cannom D.S. et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) // J. Am. Coll. Cardiol. 2006. V.48. P. 854–906.
11. Gorin L., Fauchier L., Nonin E., de Labriolle A, Haguenoer K. et al. An- tithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score =1. Thromb Haemost, 2009; 103:833–40.
12. Hart R., Halperin J.L. Atrial fibrillation and Stroke. Concepts and controversies // Stroke. 2001. Vol. 32. P. 803–808.
13. Hart R.G., Pearce L.A., Aguilar M.I. Meta–analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. // Ann. Intern. Med. 2007. Vol. 146. P. 857–67.
14. Hirsh J. et al. ACA/ACC Expert Consensus Document on Warfarin Therapy American Heart Association/American College of Cardiol- ogy Foundation Guide to Warfarin Therapy. JACC 2003; 41: 633–52.
15. Kubitza D., Becka M., Mueck W., Zuehlsdorf M. Co-administration of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – and clopi- dogrel in healthy subjects. Eur Heart J 2007; 28 Suppl1:Abstract 189.
16. Kubitza D., Becka M., Mueck W., Zuehlsdorf M. Rivaroxaban (BAY59- 7939) – an oral, direct Factor Xa inhibitor has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007;63: 469–76.
17. Kubitza D., Becka M., Mueck W., Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban – an oral, direct Factor Xa inhibitor – are not affected by aspirin. J Clin Pharmacol 2006; 46:981–90.
18. Kubitza D., Becka M., Zuehlsdorf M., Mueck W. No interaction between the novel, oral direct Factor Xa inhibitor BAY59-7939 and digoxin. J Clin Pharmacol 2006; 46:Abstract11.
19. Lee B.H., Park J.S., Park J.H., Park J.S., Kwak J.J. et al. The effect and safety of the Antithrombotic therapies in patients with atrial fibrillation and CHADS score 1. J Cardiovasc Electrophysiol, 2010 May;21(5):501–7.
20. Lin H.J., Wolf P.A., Kelly–Hayes V. et al. Stroke severity in atrial fibrillation //The Framingham Study. 1996. Vol. 27. P. 1760–1764. 21. Lip G.Y., Edwards S.J. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non–valvular atrial fibrillation: a systematic review and meta–analysis. // Thromb. Res. 2006. Vol. 118. P. 321–333.
21. Lip G.Y. H., Nieuwlaat R., Pisters R., et al Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor–Based Approach The Euro Heart Survey on Atrial Fibrillation. CHEST, 2010; 137:263–72.
22. Mann K.G., Brummel K., Butenas S. What is all that thrombin for? J Thromb Haemost 2003; 1:1501–14.
23. Ogilvie I.M., Newton N., Welner S.A., Cowell W., Lip G.Y. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010 Jul;123(7):638–645.
24. Olsen T.S., Rasmussen B.H., Kammersgaard L.P., Germer U. Strokes attributable to underuse of warfarin and antiplatelets. J Stroke Cerebrovasc Dis. 2005 Mar-Apr;14(2):55–7.
25. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E. et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91. Epub 2011 Aug 10.
26. Patrono C., Bachman F., Baigent C. et al. Expert consensus on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 2004; 25: 166–81.
27. Ryden L., Fuster V. Artrial fibrillation 2006. ESC guidelines desk reference. ESC committee for practice guidelines. To improve the quality of clinical practice and patient care in Europe. Cardiovascular medicine. Compendium of abridged ESC guidelines. 2008. P. 237–57.
28. Schwarz U.I., Ritchie M.D., Bradford Y. et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358(10):999–1008.
29. Segal J.B., McNamara R.L., Miller M.R. et al. Anticoagulants or anti-platelet therapy for non-rheumatic atrial fibrillation and flutter // Cochrane Library. 2001. Iss.1.
30. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal (2010) 31, 2369–2429.
31. Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. The Clinical Quality Improvement Network (CQIN) Investigators //Can. J. Cardiol. 1998. Vol. 14. No 5. P. 695–702.
32. Villani G., Piepoli M., Villani P., Capucci A. Anticoagulation in atrial fibrillation: what is certain and what is to come // Eur. Heart J. 2003. Vol. 5. Suppl. H. P. H45–H50.
33. Voller H., Dovifat C., Glatz J. Home management of anticoagulation // Eur. Herat J. 2001. Vol. 3. Suppl. Q. P. Q44–Q49.
34. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. // Stroke. 1991. Vol. 22. P. 983–988.
Review
For citations:
Сторожаков Г.И., Борисов С.Н., Гендлин Г.Е., Мелехов А.В. ПРИМЕНЕНИЕ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ ПРИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ И НОВЫЕ ВОЗМОЖНОСТИ. The Russian Archives of Internal Medicine. 2013;(2):57-64. (In Russ.) https://doi.org/10.20514/2226-6704-2013-0-2-57-64
Views:
1111
Email this article 